Latest Breaking News On - நிறுவனர் ஆஃப் தி நிறுவனம் - Page 5 : comparemela.com

  Gaithersburg, Maryland - 4 February 2021:   MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences company, announces that further to the announcement of a £40 million (approx. $55 million) Subscription via a private placement of 5,740,000 new shares of common stock (the Subscription Announcement ) on 3 February, 2021, Doug Doerfler, Chief Executive Officer and a Founder of the Company, Ron Holtz, Senior Vice President and Chief Accounting Officer  and J. Stark Thompson, Non-Executive Chairman, have exercised options in the amount of  755,000 shares of common stock,  $0.01 par, of the Company ( Common Stock ) ( Exercise ) in aggregate. The 755,000 new shares of Common Stock issued pursuant to the Exercise ( New Options Common Stock ) have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at a price of 700 pence per Common Stock ( Sale ).

United statesCity ofUnited kingdomNick adamsDoug doerflerEmma earlChris welshDuncan monteithJames blackMary jane elliottFreddy crossleyPanmure gordonRon holtzRupert deardenMaxcyte incLondon stock exchange